Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products includes KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal p